Fundamental studies on the mechanism of action of a novel sirtuin inhibitor (BZD9L 1) in colorectal cancer cells- towards the elucidation of a novel cancer therapeutic agent.
| dc.contributor.author | Chern Ein, Oon | |
| dc.date.accessioned | 2017-10-03T08:15:25Z | |
| dc.date.available | 2017-10-03T08:15:25Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Gemcitabine remains the standard treatment for pancreatic cancer. although most patients acquire resistance to the therapy. Up-regulated in pancreatic cancer. SIRTI is involved in tumorigenesis and drug resistance, However the mechanism through which SIRTl regulates drug sensitivity in cancer cells is mainly unknown. | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/4794 | |
| dc.subject | novel sirtuin inhibitor | en_US |
| dc.subject | cancer therapeutic | en_US |
| dc.title | Fundamental studies on the mechanism of action of a novel sirtuin inhibitor (BZD9L 1) in colorectal cancer cells- towards the elucidation of a novel cancer therapeutic agent. | en_US |
| dc.type | Technical Report | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: